FDA approves Lisraya for dermatomyositis in adults
The U.S. Food and Drug Administration has approved Lisraya (brepocitinib) tablets as the first oral treatment for dermatomyositis in adults.
Sep 1, 2026
0
5
MeSH tree: C10.668.491.562
The U.S. Food and Drug Administration has approved Lisraya (brepocitinib) tablets as the first oral treatment for dermatomyositis in adults.
Sep 1, 2026
0
5
Patients who developed myocarditis within the first month of receiving immune checkpoint inhibitor therapy were more likely to die of myocarditis, and myocarditis-specific fatality was more common in patients who experienced ...
Apr 21, 2026
0
4
An international research team with the participation of researchers from the University Medical Center Göttingen (UMG), Germany, has developed a mouse model that offers new insights into the development of a rare but serious ...
Apr 19, 2026
0
10
For adults with dermatomyositis, brepocitinib, an oral tyrosine kinase 2/Janus kinase 1 inhibitor, demonstrates significant benefits at a 30-mg dose compared with placebo, according to a study published online March 28 in ...
Apr 1, 2026
0
2
High-intensity interval training boosts fitness and muscle endurance more effectively than traditional home exercise programs in people recently diagnosed with inflammatory muscle disease. That is the conclusion of a new ...
Nov 28, 2025
0
72
A peek inside some leading research labs shows how scientists-turned-detectives are painstakingly decoding what causes autoimmune diseases and how to stop the immune system from attacking you instead of protecting you.
Nov 13, 2025
0
16
Our immune system has a dark side: It's supposed to fight off invaders to keep us healthy. But sometimes it turns traitor and attacks our own cells and tissues.
Nov 6, 2025
0
31
Autoimmune neuromuscular diseases may sound complex, but understanding them is the first step to getting the right care and support. Conditions such as Lambert-Eaton myasthenic syndrome (LEMS), myasthenia gravis (MG), and ...
Oct 23, 2025
0
17
Children with a rare, debilitating muscle disease could benefit from the findings of new research by experts at UCL and Great Ormond Street Hospital (GOSH).
Sep 10, 2025
0
18
Researchers at Friedrich-Alexander-Universität Erlangen-Nürnberg have identified a previously undocumented, organ-specific toxicity linked to CD19-targeted CAR T-cell therapy in autoimmune disease. The syndrome, termed local ...